Mice transgenic for a soluble form of murine cytotoxic T lymphocyte antigen 4 are refractory to murine acquired immune deficiency sydrome development

This publication has 36 references indexed in Scilit:

• In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).
  The Journal of Experimental Medicine, 1994
• Resistance to Murine Acquired Immunodeficiency Syndrome (MAIDS)
  Science, 1994
• The B7 and CD28 receptor families
  Immunology Today, 1994
• The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation
  Published by Elsevier ,1994
• Population Dynamics of CD4+ T Cells Lacking Thy-1 in Murine Retrovirus-Induced Immunodeficiency Syndrome (MAIDS)
  Scandinavian Journal of Immunology, 1994
• Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule
  Science, 1992
• Sites of specific B cell activation in primary and secondary responses to T cell‐dependent and T cell‐independent antigens
  European Journal of Immunology, 1991
• A unique subset of normal murine CD4⁺ T cells lacking Thy‐1 is expanded in a murine retrovirus‐induced immunodeficiency syndrome, MAIDS
  European Journal of Immunology, 1990
• Immunodeficiency and Clonal Growth of Target Cells Induced by Helper-Free Defective Retrovirus
  Science, 1989
• CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS).
  The Journal of Experimental Medicine, 1988